Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TEX26 antisense RNA 1 (TEX26-AS1, also known as LINC00447, long intergenic non-protein coding RNA 447) is a long non-coding RNA (lncRNA) mapped to chromosome 13 (positions chr13:30881933-30933846 on the hg38 genome)[3][4]. As an antisense transcript, TEX26-AS1 is thought to regulate the sense gene TEX26, potentially influencing its expression post-transcriptionally and/or by modulating transcriptional activity[5][7]. Like other antisense and long non-coding RNAs, it may play roles in chromatin organization, transcriptional interference, and gene regulation but has not been described as a therapeutic target, receptor, enzyme, transporter, or marker in current literature[3][5][6][7]. There are no known biomarkers, disease associations, or pharmacological interactions reported specifically for TEX26-AS1. While “LINC00447” and related alternatives are correctly associated as aliases, there is no current evidence for TEX26-AS1 being directly involved in a disease mechanism or being a direct molecular therapeutic target[3][4][5]. Information about its functions is inferred from general knowledge about lncRNAs and antisense RNAs; there are no specific experimental or clinical studies directly concerning TEX26-AS1[6][7]. If considering structure for databases, TEX26-AS1 is best categorized under “long non-coding RNAs” and “regulatory antisense transcripts,” but it does not fulfill criteria for inclusion as a classic drug or therapeutic target (such as receptor, enzyme, or transporter)[6][7]. If future research identifies TEX26-AS1 as relevant in disease or therapy, these classifications should be updated accordingly.
Not applicable (no drugs targeting TEX26-AS1 identified)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TEX26 antisense RNA 1 (non-protein coding) (TEX26-AS1).